Published in Mod Pathol on June 18, 2010
Transformation of the fallopian tube secretory epithelium leads to high-grade serous ovarian cancer in Brca;Tp53;Pten models. Cancer Cell (2013) 2.81
Secretory cell outgrowth, PAX2 and serous carcinogenesis in the Fallopian tube. J Pathol (2010) 1.32
Molecular and functional characteristics of ovarian surface epithelial cells transformed by KrasG12D and loss of Pten in a mouse model in vivo. Oncogene (2011) 1.29
Restoration of miR-200c to ovarian cancer reduces tumor burden and increases sensitivity to paclitaxel. Mol Cancer Ther (2012) 1.26
Combined image and genomic analysis of high-grade serous ovarian cancer reveals PTEN loss as a common driver event and prognostic classifier. Genome Biol (2014) 1.11
Recent concepts of ovarian carcinogenesis: type I and type II. Biomed Res Int (2014) 1.11
Fallopian tube correlates of ovarian serous borderline tumors. Am J Surg Pathol (2011) 0.95
Alterations in nuclear pore architecture allow cancer cell entry into or exit from drug-resistant dormancy. Am J Pathol (2011) 0.86
PAX Genes in Cancer; Friends or Foes? Front Genet (2012) 0.85
Early detection of ovarian and fallopian tube cancer by examination of cytological samples from the endometrial cavity. Br J Cancer (2013) 0.84
PTEN loss and HOXA10 expression are associated with ovarian endometrioid adenocarcinoma differentiation and progression. Carcinogenesis (2012) 0.83
Letter to the editor regarding 'Roh MH, Lassin Y, Miron A et al. High-grade fimbrial-ovarian carcinomas are unified by p53, PTEN and PAX2 expression'. Mod Pathol (2011) 0.81
PAX2 Expression in Ovarian Cancer. Int J Mol Sci (2013) 0.80
BRCA1-mediated signaling pathways in ovarian carcinogenesis. Funct Integr Genomics (2011) 0.79
Risk prediction model for epithelial ovarian cancer using molecular markers and clinical characteristics. J Ovarian Res (2015) 0.79
Early preinvasive lesions in ovarian cancer. Biomed Res Int (2014) 0.79
MUC1 positive, Kras and Pten driven mouse gynecologic tumors replicate human tumors and vary in survival and nuclear grade based on anatomical location. PLoS One (2014) 0.78
Effects of Kras activation and Pten deletion alone or in combination on MUC1 biology and epithelial-to-mesenchymal transition in ovarian cancer. Oncogene (2016) 0.77
Serous tubal intraepithelial neoplasia: the concept and its application. Mod Pathol (2017) 0.76
Morphologic correlates of molecular alterations in extrauterine Müllerian carcinomas. Mod Pathol (2016) 0.76
PAX2 function, regulation and targeting in fallopian tube-derived high-grade serous ovarian cancer. Oncogene (2016) 0.75
X chromosomal abnormalities in basal-like human breast cancer. Cancer Cell (2006) 7.17
p63 Is essential for the proliferative potential of stem cells in stratified epithelia. Cell (2007) 6.50
Breast-cancer stromal cells with TP53 mutations and nodal metastases. N Engl J Med (2007) 6.47
Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship. Am J Surg Pathol (2007) 5.68
Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. J Clin Oncol (2010) 5.50
A recurrent mutation in PALB2 in Finnish cancer families. Nature (2007) 4.64
Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy. Science (2011) 4.46
Prevalence of pathogenic BRCA1 mutation carriers in 5 US racial/ethnic groups. JAMA (2007) 4.33
p63 protects the female germ line during meiotic arrest. Nature (2006) 3.98
The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. Am J Surg Pathol (2006) 3.96
Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction. J Clin Oncol (2007) 3.94
Germline gain-of-function mutations in SOS1 cause Noonan syndrome. Nat Genet (2006) 3.81
Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res (2005) 3.41
Residual embryonic cells as precursors of a Barrett's-like metaplasia. Cell (2011) 3.36
Genome-wide association analysis identifies three new breast cancer susceptibility loci. Nat Genet (2012) 3.20
The distal fallopian tube: a new model for pelvic serous carcinogenesis. Curr Opin Obstet Gynecol (2007) 3.02
Distal airway stem cells yield alveoli in vitro and during lung regeneration following H1N1 influenza infection. Cell (2011) 3.00
Unique recurrence patterns of cervical intraepithelial neoplasia after excision of the squamocolumnar junction. Int J Cancer (2014) 2.74
A candidate precursor to pelvic serous cancer (p53 signature) and its prevalence in ovaries and fallopian tubes from women with BRCA mutations. Gynecol Oncol (2008) 2.65
Molecular and pathologic aspects of endometrial carcinogenesis. J Clin Oncol (2006) 2.59
Recursive SVM feature selection and sample classification for mass-spectrometry and microarray data. BMC Bioinformatics (2006) 2.53
Serous tubal intraepithelial carcinoma: its potential role in primary peritoneal serous carcinoma and serous cancer prevention. J Clin Oncol (2008) 2.50
Single nucleotide polymorphisms and risk of recurrence of renal-cell carcinoma: a cohort study. Lancet Oncol (2012) 2.44
Serous carcinogenesis in the fallopian tube: a descriptive classification. Int J Gynecol Pathol (2008) 2.42
Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk. PLoS Genet (2013) 2.39
Radical retropubic prostatectomy and robotic-assisted laparoscopic prostatectomy: likelihood of positive surgical margin(s). Urology (2010) 2.31
BRCA1 supports XIST RNA concentration on the inactive X chromosome. Cell (2002) 2.24
Endocervical adenocarcinoma in situ with ovarian metastases: a unique variant with potential for long-term survival. Int J Gynecol Pathol (2010) 2.16
Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers. Hum Mol Genet (2009) 2.13
Breast cancer risk for noncarriers of family-specific BRCA1 and BRCA2 mutations: findings from the Breast Cancer Family Registry. J Clin Oncol (2011) 2.13
Lessons from BRCA: the tubal fimbria emerges as an origin for pelvic serous cancer. Clin Med Res (2007) 2.12
Loss of heterozygosity and its correlation with expression profiles in subclasses of invasive breast cancers. Cancer Res (2004) 2.05
Trimodal spectroscopy for the detection and characterization of cervical precancers in vivo. Am J Obstet Gynecol (2002) 2.02
Specific down-modulation of Notch1 signaling in cervical cancer cells is required for sustained HPV-E6/E7 expression and late steps of malignant transformation. Genes Dev (2002) 1.97
Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction. Cancer Res (2010) 1.90
Loss of p63 expression is associated with tumor progression in bladder cancer. Am J Pathol (2002) 1.88
NAD(P)H and collagen as in vivo quantitative fluorescent biomarkers of epithelial precancerous changes. Cancer Res (2002) 1.88
Stathmin 1, a marker of PI3K pathway activation and regulator of microtubule dynamics, is expressed in early pelvic serous carcinomas. Gynecol Oncol (2011) 1.87
Precursors to pelvic serous carcinoma and their clinical implications. Gynecol Oncol (2009) 1.87
Multidisciplinary care and pursuit of active surveillance in low-risk prostate cancer. J Clin Oncol (2012) 1.86
Cyclin D1 as a diagnostic immunomarker for endometrial stromal sarcoma with YWHAE-FAM22 rearrangement. Am J Surg Pathol (2012) 1.83
19p13.1 is a triple-negative-specific breast cancer susceptibility locus. Cancer Res (2012) 1.81
Combined total genome loss of heterozygosity scan of breast cancer stroma and epithelium reveals multiplicity of stromal targets. Cancer Res (2004) 1.76
BRCA1 promoter methylation in sporadic breast tumors: relationship to gene expression profiles. Breast Cancer Res Treat (2005) 1.73
The Li-Fraumeni syndrome (LFS): a model for the initiation of p53 signatures in the distal Fallopian tube. J Pathol (2010) 1.70
Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342. Breast Cancer Res (2006) 1.69
Altered proliferation and differentiation properties of primary mammary epithelial cells from BRCA1 mutation carriers. Cancer Res (2009) 1.66
A comprehensive analysis of PAX8 expression in human epithelial tumors. Am J Surg Pathol (2011) 1.64
A discrete population of squamocolumnar junction cells implicated in the pathogenesis of cervical cancer. Proc Natl Acad Sci U S A (2012) 1.64
Distinction between endometrial and endocervical adenocarcinoma: an immunohistochemical study. Int J Gynecol Pathol (2002) 1.63
Coexisting intraepithelial serous carcinomas of the endometrium and fallopian tube: frequency and potential significance. Int J Gynecol Pathol (2009) 1.62
Genomic instability within tumor stroma and clinicopathological characteristics of sporadic primary invasive breast carcinoma. JAMA (2007) 1.60
HPV testing. Visible expectations and hidden realities. Am J Clin Pathol (2003) 1.59
PAX8 reliably distinguishes ovarian serous tumors from malignant mesothelioma. Am J Surg Pathol (2010) 1.57
Evidence of gene-environment interactions between common breast cancer susceptibility loci and established environmental risk factors. PLoS Genet (2013) 1.56
PAX8 Expression in well-differentiated pancreatic endocrine tumors: correlation with clinicopathologic features and comparison with gastrointestinal and pulmonary carcinoid tumors. Am J Surg Pathol (2010) 1.54
Eosinophilic dysplasia of the cervix: a newly recognized variant of cervical squamous intraepithelial neoplasia. Am J Surg Pathol (2004) 1.54
Human papillomavirus E7 oncoprotein induces KDM6A and KDM6B histone demethylase expression and causes epigenetic reprogramming. Proc Natl Acad Sci U S A (2011) 1.53
Oncogenic mutations in cervical cancer: genomic differences between adenocarcinomas and squamous cell carcinomas of the cervix. Cancer (2013) 1.52
Microglandular hyperplasia: a model for the de novo emergence and evolution of endocervical reserve cells. Hum Pathol (2005) 1.52
14-3-3 fusion oncogenes in high-grade endometrial stromal sarcoma. Proc Natl Acad Sci U S A (2012) 1.51
Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers. Hum Mol Genet (2011) 1.51
Management of endometrial precancers. Obstet Gynecol (2012) 1.47
Development and validation of a scalable next-generation sequencing system for assessing relevant somatic variants in solid tumors. Neoplasia (2015) 1.44
Allelic imbalance in BRCA1 and BRCA2 gene expression is associated with an increased breast cancer risk. Hum Mol Genet (2008) 1.43
BRCA2 mutation-associated breast cancers exhibit a distinguishing phenotype based on morphology and molecular profiles from tissue microarrays. Am J Surg Pathol (2007) 1.43
Targeted tumor-penetrating siRNA nanocomplexes for credentialing the ovarian cancer oncogene ID4. Sci Transl Med (2012) 1.42
Intestinal-type endocervical adenocarcinoma in situ: an immunophenotypically distinct subset of AIS affecting older women. Am J Surg Pathol (2013) 1.42
Evidence supporting the existence of benign teratomas of the postpubertal testis: a clinical, histopathologic, and molecular genetic analysis of 25 cases. Am J Surg Pathol (2013) 1.42
Peritoneal dissemination complicating morcellation of uterine mesenchymal neoplasms. PLoS One (2012) 1.42
BRCA1 and BRCA2 mutation carriers in the Breast Cancer Family Registry: an open resource for collaborative research. Breast Cancer Res Treat (2008) 1.40
Meningothelial proliferations in mature cystic teratoma of the ovary: evidence for the common presence of cranially derived tissues paralleling anterior embryonic plate development. An analysis of 25 consecutive cases. Am J Surg Pathol (2010) 1.40
Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriers. Breast Cancer Res (2012) 1.38
Overexpression of elafin in ovarian carcinoma is driven by genomic gains and activation of the nuclear factor kappaB pathway and is associated with poor overall survival. Neoplasia (2010) 1.36
SIK1 couples LKB1 to p53-dependent anoikis and suppresses metastasis. Sci Signal (2009) 1.35
Profiles of genomic instability in high-grade serous ovarian cancer predict treatment outcome. Clin Cancer Res (2012) 1.35
Secretory cell outgrowth, PAX2 and serous carcinogenesis in the Fallopian tube. J Pathol (2010) 1.32
Angiogenic mRNA and microRNA gene expression signature predicts a novel subtype of serous ovarian cancer. PLoS One (2012) 1.31